Elena Prado-Mel· @Epramel · X·· 21 小时前评分70
正文 · 机器翻译
HORIZON-Breast06 在 HER2-low 患者中：疾病进展风险大幅降低，其活性进一步强化了抗 HER2 ADC 在 HER2 +++ 之外的作用。需等待 OS 数据成熟，并确认长期安全性，尤其是 ILD 和血液学毒性。#ESMO26 #BCSM
61 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA13按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.orgHORIZON-Breast06: Trastuzumab Rezetecan in HER2-Low Metastatic #BreastCancer — A Major PFS Benefit, With OS and Long-Term Safety Requiring Further Follow-Up @OncoAlert #ESMO26 @myESMO #Bcsm在 X 查看被引用的帖子
来源：Elena Prado-Mel · x.com